199 related articles for article (PubMed ID: 34401220)
1. Barriers to utilization of three colorectal cancer screening options - Data from a national survey.
Zhu X; Parks PD; Weiser E; Jacobson DJ; Limburg PJ; Finney Rutten LJ
Prev Med Rep; 2021 Dec; 24():101508. PubMed ID: 34401220
[TBL] [Abstract][Full Text] [Related]
2. National Survey of Patient Factors Associated with Colorectal Cancer Screening Preferences.
Zhu X; Parks PD; Weiser E; Fischer K; Griffin JM; Limburg PJ; Finney Rutten LJ
Cancer Prev Res (Phila); 2021 May; 14(5):603-614. PubMed ID: 33888515
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
4. Health Care Provider Characteristics Associated With Colorectal Cancer Screening Preferences and Use.
Finney Rutten LJ; Parks PD; Weiser E; Fan C; Jacobson DJ; Jenkins GD; Zhu X; Griffin JM; Limburg PJ
Mayo Clin Proc; 2022 Jan; 97(1):101-109. PubMed ID: 34920895
[TBL] [Abstract][Full Text] [Related]
5. The impact of multi-target stool DNA testing in clinical practice in the United States: A real-world evidence retrospective study.
Miller-Wilson LA; Limburg P; Helmueller L; João Janeiro M; Hartlaub P
Prev Med Rep; 2022 Dec; 30():102045. PubMed ID: 36531100
[TBL] [Abstract][Full Text] [Related]
6. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
8. Impact of Patient Adherence to Stool-Based Colorectal Cancer Screening and Colonoscopy Following a Positive Test on Clinical Outcomes.
Fendrick AM; Fisher DA; Saoud L; Ozbay AB; Karlitz JJ; Limburg PJ
Cancer Prev Res (Phila); 2021 Sep; 14(9):845-850. PubMed ID: 34021023
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer screening completion: An examination of differences by screening modality.
Finney Rutten LJ; Jacobson DJ; Jenkins GD; Fan C; Weiser E; Parks P; Doroshenk M; Limburg PJ; St Sauver JL
Prev Med Rep; 2020 Dec; 20():101202. PubMed ID: 32995145
[TBL] [Abstract][Full Text] [Related]
10. Colorectal cancer screening uptake and adherence by modality at a large tertiary care center in the United States: a retrospective analysis.
Cheney C; Parish A; Niedzwiecki D; Oko C; Walters C; Halpern D; Helmueller L; Hoyek NE; Miller-Wilson LA; Sullivan BA
Curr Med Res Opin; 2024 Mar; 40(3):431-439. PubMed ID: 38197407
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing colorectal cancer screening decision-making among average-risk US adults.
Zhu X; Weiser E; Griffin JM; Limburg PJ; Finney Rutten LJ
Prev Med Rep; 2022 Dec; 30():102047. PubMed ID: 36531086
[TBL] [Abstract][Full Text] [Related]
12. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
13. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
[No Abstract] [Full Text] [Related]
14. Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing.
Cooper GS; Grimes A; Werner J; Cao S; Fu P; Stange KC
J Am Board Fam Med; 2021; 34(1):61-69. PubMed ID: 33452083
[TBL] [Abstract][Full Text] [Related]
15. Alaska Native Patient and Provider Perspectives on the Multitarget Stool DNA Test Compared With Colonoscopy for Colorectal Cancer Screening.
Redwood DG; Blake ID; Provost EM; Kisiel JB; Sacco FD; Ahlquist DA
J Prim Care Community Health; 2019; 10():2150132719884295. PubMed ID: 31646933
[No Abstract] [Full Text] [Related]
16. Cost-Effectiveness of Multitarget Stool DNA Testing vs Colonoscopy or Fecal Immunochemical Testing for Colorectal Cancer Screening in Alaska Native People.
Redwood DG; Dinh TA; Kisiel JB; Borah BJ; Moriarty JP; Provost EM; Sacco FD; Tiesinga JJ; Ahlquist DA
Mayo Clin Proc; 2021 May; 96(5):1203-1217. PubMed ID: 33840520
[TBL] [Abstract][Full Text] [Related]
17. Estimating the impact of differential adherence on the comparative effectiveness of stool-based colorectal cancer screening using the CRC-AIM microsimulation model.
Piscitello A; Saoud L; Fendrick AM; Borah BJ; Hassmiller Lich K; Matney M; Ozbay AB; Parton M; Limburg PJ
PLoS One; 2020; 15(12):e0244431. PubMed ID: 33373409
[TBL] [Abstract][Full Text] [Related]
18. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
[TBL] [Abstract][Full Text] [Related]
19. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model.
Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ
Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894
[TBL] [Abstract][Full Text] [Related]
20. Colorectal Cancer screening in ambulatory healthcare service clinics in Abu Dhabi, United Arab Emirates in 2015-2016.
Almansoori A; Alzaabi M; Alketbi L
BMC Cancer; 2021 Aug; 21(1):897. PubMed ID: 34362343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]